source
- Amgen initiates three late-stage trials of obesity shot MariTide, including a switch-patient studyAmgen announced the start of three new Phase 3 trials for its long-acting obesity injection, MariTide. One of the studies will enroll participants who are transitioning away from the GLP-1 therapi…
- Seaport and Hemab price IPOs as Avalyn soars on Nasdaq debutThree biotechnology companies announced the pricing of their initial public offerings between Thursday and Friday, collectively targeting more than $850 million in proceeds. Seaport Therapeutics a…